SameerDesaiMD(He/Him)

Clinical Trials

• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. Start of enrollment: 2021 Dec 22

  Withdrawn

  Phase 1, Phase 2

• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Start of enrollment: 2022 Mar 04

  Recruiting

  Phase 3

• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer Start of enrollment: 2023 Jan 24

  Recruiting

  Phase 1, Phase 2

• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies Start of enrollment: 2022 Feb 01

  Recruiting

  Phase 2

• A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. Start of enrollment: 2023 Mar 03

  Recruiting

  Phase 3

• A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Start of enrollment: 2021 Sep 15

  Active, not recruiting

  Phase 1, Phase 2

• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Start of enrollment: 2020 Oct 09

  Active, not recruiting

  Phase 3

• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2020 Aug 24

  Active, not recruiting

  Phase 3

• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Start of enrollment: 2023 Jan 11

  Recruiting

  Phase 3

• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Start of enrollment: 2021 Nov 17

  Active, not recruiting

  Phase 3

• Join now to see all